Current replication
Spearman rank correlation
0.83Measured 2026-09-27
View this run ↗Public Health · 2020
Individual preferences for COVID-19 vaccination in China
In China, efficacy, side effects and vaccinated acquaintances mattered most.
Read the paper ↗01 / Human finding
What the study found
In China, efficacy, side effects and vaccinated acquaintances mattered most.
Answer-key review: AI-reviewed
02 / Experiment design
Who chose, and what varied
- Country
- China
- Human respondents
- 1883
- Attributes
- 7
- Task
- discrete choice
03 / Synthetic replication
Registry replication results
Paper-era reference
2023 CLM mean Spearman ρ
0.56Historical results use their original estimator and reference. They are not a matched comparison with the current run.
Detailed replication evidence · 2026-10-02
Right direction on all 11 significant effects, close ranking (ρ = 0.83); sizes not comparable (the paper reports logit coefficients).
Use it to screen and rank which attributes move choice; sizes need the paper's respondent data.
- direction
- holds
- rank
- holds
- size
- not comparable
Supported uses
- Screening which attributes move choice, and in which direction.
- Ranking attributes and levels by how strongly they move choice.
Limits to keep in view
- Effect sizes in the paper's units; only direction, rank and shape are compared.
Effects on a common scale
Human effects: logit coefficient. Synthetic effects are multiplied by the record’s calibration factor, k = 2.2324. Calibration aligns magnitude; it does not establish agreement in unadjusted effect sizes.
| Attribute / level | Human | Human 95% half-width | Calibrated synthetic |
|---|---|---|---|
| Vaccine efficacy: This vaccine protects 40% of vaccinated (reference) | 0.000 | Not measured | 0.000 |
| Vaccine efficacy: This vaccine protects 60% of vaccinated | 0.389 | 0.051 | 0.414 |
| Vaccine efficacy: This vaccine protects 85% of vaccinated | 0.994 | 0.053 | 0.798 |
| Major adverse effect rate: 50 out of 100000 risk a severe side effect (reference) | 0.000 | Not measured | 0.000 |
| Major adverse effect rate: 10 out of 100000 risk a severe side effect | 0.469 | 0.051 | 0.357 |
| Major adverse effect rate: 1 out of 100000 risk a severe side effect | 0.932 | 0.053 | 0.592 |
| Vaccine access: This vaccine is free and it is voluntary to get vaccinated (reference) | 0.000 | Not measured | 0.000 |
| Vaccine access: This vaccine is free and it is compulsory to get vaccinated | 0.025 | 0.051 | -0.220 |
| Vaccine access: You must pay for vaccine yourself and vaccination is voluntary | -0.279 | 0.051 | -0.478 |
| Vaccine doses: Full vaccination requires one dose (reference) | 0.000 | Not measured | 0.000 |
| Vaccine doses: Full vaccination requires two or more doses | -0.057 | 0.035 | -0.156 |
| Vaccination sites: Vaccination is provided in a village clinic or community health station (reference) | 0.000 | Not measured | 0.000 |
| Vaccination sites: Vaccination is provided in a township or community health centre | -0.030 | 0.053 | 0.177 |
| Vaccination sites: Vaccination is provided in a county hospital and above | 0.073 | 0.051 | 0.293 |
| Protection duration: This vaccine provides six months of protection (reference) | 0.000 | Not measured | 0.000 |
| Protection duration: This vaccine provides one year of protection | 0.152 | 0.049 | 0.071 |
| Protection duration: This vaccine provides more than two years of protection | 0.257 | 0.051 | 0.216 |
| Vaccine uptake: 30% of your family friends and acquaintances already vaccinated (reference) | 0.000 | Not measured | 0.000 |
| Vaccine uptake: 60% of your family friends and acquaintances already vaccinated | 0.155 | 0.051 | 0.109 |
| Vaccine uptake: 90% of your family friends and acquaintances already vaccinated | 0.257 | 0.051 | 0.190 |
04 / Evidence and limitations
Follow the evidence
Missing results mean unmeasured, not zero agreement.